Literature DB >> 30332313

Periostin overexpression in collecting ducts accelerates renal cyst growth and fibrosis in polycystic kidney disease.

Archana Raman1,2, Stephen C Parnell1,3, Yan Zhang1,4, Gail A Reif1,4, Yuqiao Dai1,4, Aditi Khanna1,4, Emily Daniel1,4, Corey White1,4, Jay L Vivian5, Darren P Wallace1,2,4.   

Abstract

In polycystic kidney disease (PKD), persistent activation of cell proliferation and matrix production contributes to cyst growth and fibrosis, leading to progressive deterioration of renal function. Previously, we showed that periostin, a matricellular protein involved in tissue repair, is overexpressed by cystic epithelial cells of PKD kidneys. Periostin binds αVβ3-integrins and activates integrin-linked kinase (ILK), leading to Akt/mammalian target of rapamycin (mTOR)-mediated proliferation of human PKD cells. By contrast, periostin does not stimulate the proliferation of normal human kidney cells. This difference in the response to periostin is due to elevated expression of αVβ3-integrins by cystic cells. To determine whether periostin accelerates cyst growth and fibrosis, we generated mice with conditional overexpression of periostin in the collecting ducts (CDs). Ectopic CD expression of periostin was not sufficient to induce cyst formation or fibrosis in wild-type mice. However, periostin overexpression in pcy/pcy ( pcy) kidneys significantly increased mTOR activity, cell proliferation, cyst growth, and interstitial fibrosis; and accelerated the decline in renal function. Moreover, CD-specific overexpression of periostin caused a decrease in the survival of pcy mice. These pathological changes were accompanied by increased renal expression of vimentin, α-smooth muscle actin, and type I collagen. We also found that periostin increased gene expression of pathways involved in repair, including integrin and growth factor signaling and ECM production, and it stimulated focal adhesion kinase, Rho GTPase, cytoskeletal reorganization, and migration of PKD cells. These results suggest that periostin stimulates signaling pathways involved in an abnormal tissue repair process that contributes to cyst growth and fibrosis in PKD.

Entities:  

Keywords:  autosomal dominant polycystic kidney disease; extracellular matrix; integrin; matricellular protein; proliferation

Mesh:

Substances:

Year:  2018        PMID: 30332313      PMCID: PMC6336984          DOI: 10.1152/ajprenal.00246.2018

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  75 in total

Review 1.  Practical genetics for autosomal dominant polycystic kidney disease.

Authors:  York Pei
Journal:  Nephron Clin Pract       Date:  2010-11-11

2.  Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis.

Authors:  P Darwin Bell; Wayne Fitzgibbon; Kelli Sas; Antine E Stenbit; May Amria; Amber Houston; Ryan Reichert; Sandra Gilley; Gene P Siegal; John Bissler; Mehmet Bilgen; Peter Cheng-te Chou; Lisa Guay-Woodford; Brad Yoder; Courtney J Haycraft; Brian Siroky
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

3.  Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.

Authors:  Rong Shao; Shideng Bao; Xuefang Bai; Carrie Blanchette; Ryan M Anderson; Tongyun Dang; Mikhail L Gishizky; Jeffrey R Marks; Xiao-Fan Wang
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

4.  Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.

Authors:  Hester Happé; Wouter N Leonhard; Annemieke van der Wal; Bob van de Water; Irma S Lantinga-van Leeuwen; Martijn H Breuning; Emile de Heer; Dorien J M Peters
Journal:  Hum Mol Genet       Date:  2009-04-28       Impact factor: 6.150

5.  Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.

Authors:  Tamio Yamaguchi; Darren P Wallace; Brenda S Magenheimer; Scott J Hempson; Jared J Grantham; James P Calvet
Journal:  J Biol Chem       Date:  2004-07-19       Impact factor: 5.157

Review 6.  Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach.

Authors:  Jared J Grantham
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

7.  Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling.

Authors:  Alexander F Palazzo; Christina H Eng; David D Schlaepfer; Eugene E Marcantonio; Gregg G Gundersen
Journal:  Science       Date:  2004-02-06       Impact factor: 47.728

8.  Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat.

Authors:  S Nagao; K Nishii; D Yoshihara; H Kurahashi; K Nagaoka; T Yamashita; H Takahashi; T Yamaguchi; J P Calvet; D P Wallace
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

9.  Epidermal growth factor precursor is present in a variety of human renal cyst fluids.

Authors:  D W Moskowitz; S L Bonar; W Liu; C F Sirgi; M D Marcus; R V Clayman
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

10.  Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease.

Authors:  Darren P Wallace; Corey White; Lyudmyla Savinkova; Emily Nivens; Gail A Reif; Cibele S Pinto; Archana Raman; Stephen C Parnell; Simon J Conway; Timothy A Fields
Journal:  Kidney Int       Date:  2013-11-27       Impact factor: 10.612

View more
  9 in total

1.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

Review 2.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

3.  Novel Targets for Therapy of Renal Fibrosis.

Authors:  Niki Prakoura; Juliette Hadchouel; Christos Chatziantoniou
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 4.  Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease.

Authors:  Yan Zhang; Gail Reif; Darren P Wallace
Journal:  Cell Signal       Date:  2020-04-18       Impact factor: 4.315

5.  Dietary phosphate restriction attenuates polycystic kidney disease in mice.

Authors:  Faith Omede; Shiqin Zhang; Cassandra Johnson; Emily Daniel; Yan Zhang; Timothy A Fields; Joseph Boulanger; Shiguang Liu; Ishfaq Ahmed; Shahid Umar; Darren Paul Wallace; Jason R Stubbs
Journal:  Am J Physiol Renal Physiol       Date:  2019-11-04

6.  Kidney stone formation in a novel murine model of polycystic kidney disease.

Authors:  Heather A L Riddle; Shiqin Zhang; Feng Qian; James C Williams; Jason R Stubbs; Peter Stanley N Rowe; Stephen C Parnell
Journal:  Am J Physiol Renal Physiol       Date:  2022-03-28

Review 7.  The role of periostin in kidney diseases.

Authors:  Agnieszka Turczyn; Małgorzata Pańczyk-Tomaszewska
Journal:  Cent Eur J Immunol       Date:  2021-11-01       Impact factor: 2.085

8.  Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Johannes Leierer; Paul Perco; Benedikt Hofer; Susanne Eder; Alexander Dzien; Julia Kerschbaum; Michael Rudnicki; Gert Mayer
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

9.  Metformin attenuates renal interstitial fibrosis through upregulation of Deptor in unilateral ureteral obstruction in rats.

Authors:  Yanxia Wang; Yan Wang; Yong Li; Linghong Lu; Yingxian Peng; Shu Zhang; Anzhou Xia
Journal:  Exp Ther Med       Date:  2020-08-26       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.